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Abstract 
 
Background  
A wide range of left ventricular (LV) recovery rates on left ventricular assist device 
(LVAD) support have been reported. In this case series, we summarize our 
experience with LVAD explantation for presumed LV recovery. 
Case series 
Out of 240 patients who received an LVAD implant in our program since its 
inception, we explanted/inactivated the pump for presumed LV recovery in only 
three patients. All three of these patients had relapse of cardiomyopathy within 6 
months of explantation. 
Conclusion 
Our experience does not support the existence of LV recovery following LVAD 
implantation as a common phenomenon. Improvement in LV function on LVAD is 
sustainable only with mechanical circulatory support and once the offloading 
support provided by the device is removed recurrent failure quickly ensue. Likely 
the term “remission” reflects the status more accurately than the term “recovery”. 
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Introduction 
Since the publication of the famous paper by Birks et al. in 2006 reporting a 
stunning 73% prevalence of left ventricular (LV) recovery allowing explantation of 
previously implanted pulsatile-flow left ventricular assist devices (LVADs) with no 
recurrence of heart failure (HF), LV recovery has continued to be a controversial 
topic (1). The magnitude of recovery was first ascribed to clenubetrol, which they 
used in high doses to facilitate myocardial strength and contraction. Following this, 
in 2011, a similar study was done with a non-pulsatile LVAD (HeartMate II, 
Thoratec, Pleasanton, CA), without clenubetrol, and still demonstrated a 60% 
recovery rate (2). Meanwhile however, data from INTERMACS demonstrated LV 
recovery allowing explantation in only 0.9% at 1-year, 1.9% at 2-year, and 3.1% at 
3-year follow-up (3). Given the varied data available there is on-going debate 
regarding the true prevalence of LV recovery following LVAD implantation. 
In our center. over 250 patients have been implanted with long-term LVADs. Only 
three patients demonstrated the degree of recovery sufficient for explantation of 
their pumps, but afterward all went on to develop recurrent LV failure. We are 
presenting this case series and questioning the durability of myocardial recovery 
resulting from the mechanical unloading on LVAD. 
Case 1 
 A 55 year old male with a 10 year history of systolic heart failure secondary to a 
non-ischemic cardiomyopathy presented with progressive New York Heart 
Association (NYHA) functional class IV symptoms. At time of presentation he was 
on guideline directed medical therapy and had an implantable Cardioverter-
defibrillator (ICD) in place. The electrocardiogram (ECG) demonstrated normal 
sinus rhythm with no bundle branch block and a normal QRS duration. He 
underwent placement of a Heartmate II LVAD (Thoratec, Pleasanton, CA). His pre-
implant echo showed an LVEF of 13%. After receiving the implant, he was 
regularly followed up in LVAD clinic. He continued to be treated with a beta blocker 
and angiotensine converting enzyme (ACE) inhibitor while his LVAD was in place 
and had drastic improvement in his heart failure symptoms. An echocardiogram 
was repeated 3 months after LVAD implantation which demonstrated an LVEF of 
25-35%, which was the first evidence of some degree of myocardial recovery. One 
and a half years following device implantation he presented with altered mental 
status and was ultimately diagnosed with streptococcal pneumonia. A computer 
tomography (CT) of the chest demonstrated several abscesses within the LVAD 
pocket. Irrigation and drainage of the abscesses were performed, however the 
device itself was grossly infected. Perioperative echo with ramp study showed 
further improvement in LV function with LVEF of 40-45%. Given the patient 
demonstrated improvement in his ejection fraction and because the device was 
grossly infected, the device was removed. He was treated with appropriate 
antibiotics with clinical improvement and was discharged home with continued 
guideline directed medical therapy. Six months later, he presented with symptoms 
of heart failure, and his LVEF has declined to 30% at that time. Another 6 months 
later (total of 12 months post-explantation), a repeat echocardiogram 
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demonstrated that his LVEF had returned to less than 20%. He was admitted 
multiple times for acute decompensated heart failure exacerbations and eventually 
became inotrope dependent. He was not a candidate for repeat LVAD due to 
extensive adhesions and social limitations. Ultimately, he was referred to hospice 
care.  
Case 2  
A 48 year old male presented with 6 months of progressive dyspnea on exertion. 
He was previously healthy with no past medical history.  A transthoracic echo 
showed an LVEF 15% with no significant valvular abnormalities. He underwent 
coronary angiography which showed no obstructive coronary artery disease. He 
was started on guideline directed medical therapy titrated to maximally tolerated 
dosages and participated in a cardiac rehabilitation program. Despite appropriate 
medical therapy, he had on-going NYHA class IV heart failure symptoms, was 
placed on continuous inotropic therapy and then ultimately underwent placement 
of a Heartmate II LVAD. He continued to be treated with an ACE inhibitor and beta 
blocker. In 9 months after implantation an echocardiogram revealed an LVEF of 25 
to 35%. At 1 year post implantation, an echocardiogram was repeated, now 
demonstrating an LVEF of greater than 55%. After weaning of the pump (8600 
revolutions per minute (rpms) to 6000 rpms), serial echocardiograms continued to 
show an intact LVEF of 58 to 61% with normal LV end diastole internal dimension 
at 3.7-3.9 cm indicating the possibility of LV recovery. Right heart catheterization 
was performed, and it confirmed normal right and left heart filling pressures 
despite reduction of the LVAD speed to 6000 rpms. Given evidence of LV 
recovery, the device was explanted 15 months following implantation. Following 
device removal he was continued on guideline directed medical therapy at the 
maximally tolerated dosages. While he initially remained stable following 
explantation, within the first year he developed recurrent symptoms accompanied 
by a gradual decline in LV function. First evidence of recurrent LV failure occurred 
at 3 months post-explantation at which time LVEF has declined to 35%. The 
ejection fraction remained stable for the next 9 months before ultimately declining 
to around 20 to 25% one year after the device had been removed. At this time, he 
currently remains on heart failure medications and has not yet required re-
implantation of a LVAD or initiation of inotropic therapy.  
Case 3 
A 50 year old female with a 30 year history of systolic heart failure secondary to 
peripartum cardiomyopathy presented with progressing NYHA IV symptoms. At 
the time of presentation she was on guideline directed medical therapy, had 
undergone cardiac rehabilitation therapy, and had an ICD in place. An ECG 
demonstrated normal sinus rhythm. An echocardiogram was performed which 
demonstrated and LVEF of less than 20%, along with severe LV dilatation. As she 
was not eligible for transplant due to obesity and recent smoking, a Heartmate II 
LVAD was placed. She did well following device implantation, was continued on 
goal directed medical therapy, continued to participate in cardiac rehabilitation and 
was followed routinely in LVAD clinic. In subsequent months, her LVEF recovered 
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to 50 to 55%. The pump speed was serially reduced from 9200 rpms to 8400 
rpms, and then further to 6000 rpms, and all the while her LVEF remained stable 
at 50 to 55%. An LVAD recovery study was performed which showed normal LV 
size and function with normal intra-cardiac filling pressures on right heart 
catheterization while on minimal pump speed. With the swan-ganz catheter left in, 
she remained with normal hemodynamics for 24 hours on minimal pump speed, 
with pulmonary capillary wedge pressures staying at 12mmHg. 19 months after 
implantation, the LVAD was inactivated (because of technical difficulty and 
intraoperative bleeding, the pump was left inside with the outflow graft stapled 
closed). She was managed on appropriate medical therapy. By 3 months following 
device inactivation, her LVEF had returned to less than 20% with recurrent severe 
global hypokinesis and severe LV dilatation. She was initiated on inotropic support 
with milrinone. At present, she remains on continuous home inotropic therapy.   
The dynamic changes of echocardiographic parameters of all three patients are 
presented in Table 1. 
 
Table 1. The dynamic changes of echocardiographic parameters 
 
    
pre-
LVAD 
on 
LVAD Post-LVAD 
    
1 
week 
3 
months 
6 
months 
12 
months 
Patient 1        
 LVEDD, cm 8.4 5.0 5.0     8.0 
  LVESD, cm 6.9 3.9 3.7     7.3 
  LVEF, % 13 40 40   30 10 
  TAPSE, cm 2.0 1.4 1.5     1.3 
Patient 2           
  LVEDD, cm 7.4 4.5 5.0 5.4 6.1 5.8 
  LVESD, cm 7.0 3.2 4 5.2 5.5 5.4 
  LVEF, % 15 55 55 35 35 25 
  TAPSE, cm   1.5 1.2 1.9 1.3 1.4 
Patient 3        
 LVEDD,cm 7.6 4.4 5.5 6.5 6.6 7.1 
  LVESD, cm 7.1 3.4 5 6.1 6.3 6.7 
  LVEF, % 15 55 55 15 10 10 
  TAPSE, cm 1.9 2.0 2.0 1.5 1.0   
 
LVEDD – left ventricular end-diastolic dimension 
LVSD – left ventricular end-systolic dimension 
LVEF – left ventricular ejection fraction 
TAPSE – tricuspid annulus plane systolic excursion 
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Discussion   
Since the beginning of our program in 2003, a total of 256 patients have had long-
term LVADs implanted. Of those patients, only 3 patients demonstrated evidence 
of LV recovery allowing for either explantation or inactivation of their device. All 
patients in this case series had placement of a Heartmate II LVAD which is a 
continuous flow device, and no patients were treated with the selective beta 
agonist, clenubetrol as had been done in cited previous studies. As part of our 
institutions protocol, all patients in this series were continued on guideline directed 
medical therapy with beta blockade and ACE inhibitors that were slowly titrated to 
maximally tolerated dosages throughout the entire duration of their care - including 
prior to implantation, during implantation, and after explantation. All three patients 
had an ICD in place, however none met current guidelines for cardiac 
resynchronization therapy. Despite aggressive medical management, cardiac 
rehabilitation and close follow up all patients LVEF’s started to decline and by 1 
year all patients had developed recurrent severe LV dysfunction and significant 
symptoms.  
The experience at our institution is consistent with the above mentioned 
INTERMACS recovery rate and very different from the both recovery studies with 
pulsatile or continuous flow LVAD, with or without clenbutirol (1,2). While there is 
evidence that pulsatile LVADs do provide more offloading for the left ventricle we 
cannot equate the recovery rate to be secondary to this factor alone, given that 
recovery rates of similar magnitude were reproduced with continuous flow devices.  
In the initial study demonstrating such pronounced rate of LV recovery, patients 
were treated with clenubetrol, a selective beta-2 agonist, with the goal of the 
medication to increase myocardial strength and contractility. Later, in a small trial 
by George et al (4), 7 patients were trialed on oral clenubetrol following LVAD 
implantation and dosages were slowly titrated up. Despite a statistically significant 
increase in skeletal muscle mass, a trend towards increase LV mass and a 
significant increase in end diastolic dimension, cardiac function did not improve.  
Our experience is well aligned with data gathered from other larger datasets. We 
have evaluated this subject matter in a previous review in 2012 (5). At that time we 
evaluated several large case series of patients in an effort to decrease any random 
fluctuations secondary to small, single center studies and found that at most 
prevalence of LV recovery was 24% in these patient populations, with majority of 
these studies having rates of LV recovery in the single digits. In the INTERMACS 
database, which is composed of data from all LVAD patients, their recovery rate is 
similar to what we found in these other large case series at a 3% at three years 
(3). As INTERMACS does not have data on outcomes after LVAD explantation, we 
are unable to determine from their dataset if this 3% of patients went on to have 
sustainable, durable LV recovery following device removal or developed recurrent 
cardiomyopathies. As compared to INTERMACS, The United Network for Organ 
Sharing (UNOS) database includes only patients actively listed for transplantation, 
and frequently these patients tend to be younger and have less comorbidities than 
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the general heart failure population. Given this population is likely more similar in 
demographics to the patients represented in the recovery trials, mostly young 
people with nonischemic cardiomyopathy of recent onset (1,2), one would have 
expected the UNOS population to yield a recovery rate more similar to the trials, 
but that was not the case. In the UNOS population, only 5% of patients underwent 
LVAD explantation for LV recovery (7).  The UNOS study did look at outcomes 
after explantation, however the primary end point in their analysis was mortality at 
one year. They did not comment on development of recurrent heart failure. Using 
mortality as primary end point would skew the impression that LV recovery is more 
durable than it really is as in our case series none of our patients would have met 
the primary endpoint- all were alive one year after explantation, yet all of them had 
developed recurrent heart failure by this point (7). 
Additional evidence against complete, durable LV recovery has also been 
demonstrated at the cellular level. Improvement in cardiac size and function with 
hemodynamic unloading on LVAD is well studied. The signs include regression of 
cardiomyocyte hypertrophy, reduction of myocardial mass and myocyte size (6), 
improvement in myocyte contractility (7), , up-regulation of beta-1-adrenergic 
receptors, increase in their density, restoration of contractile response to beta-
adrenergic stimulation (8), decrease in LV dimensions and pulmonary capillary 
wedge pressure, increase in LVEF,  cardiac index and mean aortic pressure (9), 
etc. On a metabolic level, there is improvement of collagen handling in the 
ventricle (10) and a decrease in levels of circulating and intrinsic myocardial 
inflammatory mediators (11). However, the normalization is usually incomplete. In 
the samples of myocardium before and after several months of support on LVAD, 
there was no difference in capillary density, cardiac fibrosis, or macrophage 
density. On the other hand, there was a very significant - almost 17-fold decrease 
in fibroblast-specific collagen expression, showing that while macroscopically there 
were significant changes in the LV achieved by mechanical unloading, there is 
persistent abnormalities on the microscopic level in regards to cell modeling and 
gene expression (12). Reversal of the geometric alternations by mechanical 
unloading does not equate to reversal of the cellular and transcriptional machinery. 
While the LV may appear normal on echocardiography, microscopically it is not 
which creates this false illusion of complete recovery (13). 
Perhaps the major factor determining the rate of recovery in our case series, 
versus the papers by Birks et al (1,2), is patient selection. In their studies majority 
of the patients were under the age the 50, which is significantly younger than the 
typical average decompensated heart failure population. Also of note, of the 12 
people who underwent device removal, 10 had carried a diagnosis of HF for less 
than 3 years which is a relatively short time as compared to the patients in this 
series in which 2 of them had carried the diagnosis for greater than 10 years. 
These differences are also echoed in the Texas Heart Study in which 4.1% of their 
LVAD patients had successful LVAD explantation for recovery, however one-third 
of those patients who developed LV recovery were under the age of 30 when their 
device was initially implanted (14). INTERMACS data also corroborates that age < 
50 is an independent predictor of LV recovery, as is having a short duration from 
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the time of cardiac diagnosis (<2 years), a non-ischemic etiology, LVEDD < 6.5cm, 
creatinine < 1.2mg/dL and the absence of an ICD (15). 
In general, resolution of left ventricular dysfunction following LVAD implantation 
allowing device removal is likely rather the exception than the rule. Younger 
people are more prone to have acute myocarditis, alcohol or drug related disease, 
or peripartum cardiomyopathy – conditions with high rate of spontaneous recovery. 
Myocardial offloading with LVAD simply stabilizes them and gives the time to 
recover.   
If our experience is typical, myocardial recovery does not occur en masse on 
LVAD support. Hemodynamic LV unloading improves geometry and function, but 
the underlying process persists. When hemodynamic support is taken away, 
cardiomyopathy relapses within 6 months. The term “remission” is more 
appropriate than “recovery”. 
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